No Data
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $5 Price Target
Wedbush Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $5
Wedbush analyst David Nierengarten maintains $Nuvation Bio(NUVB.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 44.1% and a
Jefferies Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $10
Jefferies analyst Michael Yee maintains $Nuvation Bio(NUVB.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 42.8% and a
Strong Buy Recommendation for Nuvation Bio Based on Superior Clinical Data and Market Valuation
Express News | Xiangmin Cui Reports 8.0% Stake in Nuvation Bio as of September 3- SEC Filing
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket